Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ME 401 (Primary)
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TIDAL
  • Sponsors MEI Pharma

    • Most Recent Events

    • 09 May 2019 According to a MEI Pharma media release, the companys immediate focus is on executing this global lymphoma phase 2 study.The company intend to submit data from this study as an accelerated approval marketing application with the FDA.
    • 07 Feb 2019 According to a MEI Pharma media release, dosing of the first patient in this trial is expected in the first calendar quarter of 2019.
    • 14 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top